Pembrolizumab shows clinical promise as a treatment for mycosis fungoides and Sézary syndrome, achieving a response in nearly half of patients in a case series.

Innate Pharma has secured US Food and Drug Administration (FDA) breakthrough therapy designation for lacutamab to treat ...

Mycosis fungoides (MF) is the most common type of ... Photopheresis is an option for SE9zary syndrome, a variant of MF. With treatment and regular check-ups remission may be achieved and the ...